Vectra DA algorithm score (MBDA score) frequently indicated elevated RA disease activity when CRP was normal.

“Multi-biomarker disease activity (MBDA) scores frequently indicated RA disease activity when CRP [C-reactive protein] did not. Neither one was significantly greater among patients with RA and FM [fibromyalgia] versus RA alone. Thus, MBDA score may be a useful objective measure for identifying RA patients with active inflammation when CRP is low (41.0 mg/dl), including RA patients with concomitant FM.”

Lee YC, et al. Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. Rheumatology 2016; 55:640-8.

Learn More View Article

Vectra DA algorithm score (MBDA score) enhanced ability of conventional risk factors to predict radiographic progression.

“Radiographic progression was infrequent for low MBDA scores. Relative risk for progression increased continuously as the MBDA score increased, reaching 17.4 for change in SHS >5 with MBDA scores ≥60. Joint space narrowing and erosion progression were associated with MBDA score. MBDA score was associated with radiographic progression after adjustments for other risk factors. MBDA score significantly differentiated risk for progression when swollen joint count, CRP or DAS28–CRP was low, and among seropositive patients.”

Li W, et al. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. Rheumatology. 2016; 55(2):357-66.

Learn More View Article

Vectra DA algorithm score (MBDA score) tracks clinical response in patients with RA treated with different TNF inhibitors.

“Multi-biomarker disease activity (MBDA) scores tracked disease activity and treatment response in patients with rheumatoid arthritis (RA) treated with three TNF inhibitors.”

Hirata S, et al. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. Mod Rheumatol. 2014; 25(3):344-9.

Learn More View Article

Biomarkers provide information about underlying RA pathophysiology that may complement clinical assessment.

“The MBDA score could be used to enable monthly monitoring of disease activity while allowing clinical assessment to take place less frequently. This would provide additional information about patient status and might allow more efficient use of precious health care resources.”

Hirata S, et al. A multi‐biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford) 2013; 52:1202-7.

Learn More View Article

Vectra DA algorithm score (MBDA score) predicts radiographic progression.

“MBDA score enhanced the ability of conventional risk factors to predict radiographic progression in patients with established RA receiving non-biologic DMARDs [disease-modifying anti-rheumatic drugs].”

Li W, et al. SAT0033 characterization of the multi-biomarker disease activity (Vectra® DA algorithm) score in a subgroup of patients from the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) cohort receiving methotrexate. Ann Rheum Dis. 2013; 72:A591.

Learn More View Article

Vectra DA algorithm score (MBDA score) had significant correlation with disease activity score.

“This multi-biomarker test performed well in the assessment of disease activity in RA patients in the CAMERA study. Upon further validation, this test could be used to complement currently available disease activity measures and improve patient care and outcomes.”

Bakker M, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis. 2012; 71:1692-7.

Learn More View Article

Objective measure of RA disease activity.

“The MBDA score was significantly associated with the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) in both seropositive (AUROC 0.77, P < 0.001) and seronegative (AUROC 0.70, P < 0.001) patients.”

Curtis JR, et al. Validation of a novel biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2012; 64(12):1794–1803.

Learn More View Article


For more peer-reviewed content
Vectra DA Publication Library